Cargando…

The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future

Apomorphine is now recognized as the oldest antiparkinsonian drug on the market. Though still underused, it is increasingly prescribed in Europe for patients with advanced Parkinson’s disease (PD) with motor fluctuations. However, its history is far from being limited to movement disorders. This pap...

Descripción completa

Detalles Bibliográficos
Autores principales: Auffret, Manon, Drapier, Sophie, Vérin, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995787/
https://www.ncbi.nlm.nih.gov/pubmed/29546602
http://dx.doi.org/10.1007/s40268-018-0230-3
_version_ 1783330669415366656
author Auffret, Manon
Drapier, Sophie
Vérin, Marc
author_facet Auffret, Manon
Drapier, Sophie
Vérin, Marc
author_sort Auffret, Manon
collection PubMed
description Apomorphine is now recognized as the oldest antiparkinsonian drug on the market. Though still underused, it is increasingly prescribed in Europe for patients with advanced Parkinson’s disease (PD) with motor fluctuations. However, its history is far from being limited to movement disorders. This paper traces the history of apomorphine, from its earliest empirical use, to its synthesis, pharmacological development, and numerous indications in human and veterinary medicine, in light of its most recent uses and newest challenges. From shamanic rituals in ancient Egypt and Mesoamerica, to the treatment of erectile dysfunction, from being discarded as a pharmacological tool to becoming an essential antiparkinsonian drug, the path of apomorphine in the therapeutic armamentarium has been tortuous and punctuated by setbacks and groundbreaking discoveries. Throughout history, three main clinical indications stood out: emetic (gastric emptying, respiratory disorders, aversive conditioning), sedative (mental disorders, clinical anesthesia, alcoholism), and antiparkinsonian (fluctuations). New indications may arise in the future, both in PD (palliative care, nonmotor symptoms, withdrawal of oral dopaminergic medication), and outside PD, with promising work in neuroprotection or addiction.
format Online
Article
Text
id pubmed-5995787
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-59957872018-06-25 The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future Auffret, Manon Drapier, Sophie Vérin, Marc Drugs R D Review Article Apomorphine is now recognized as the oldest antiparkinsonian drug on the market. Though still underused, it is increasingly prescribed in Europe for patients with advanced Parkinson’s disease (PD) with motor fluctuations. However, its history is far from being limited to movement disorders. This paper traces the history of apomorphine, from its earliest empirical use, to its synthesis, pharmacological development, and numerous indications in human and veterinary medicine, in light of its most recent uses and newest challenges. From shamanic rituals in ancient Egypt and Mesoamerica, to the treatment of erectile dysfunction, from being discarded as a pharmacological tool to becoming an essential antiparkinsonian drug, the path of apomorphine in the therapeutic armamentarium has been tortuous and punctuated by setbacks and groundbreaking discoveries. Throughout history, three main clinical indications stood out: emetic (gastric emptying, respiratory disorders, aversive conditioning), sedative (mental disorders, clinical anesthesia, alcoholism), and antiparkinsonian (fluctuations). New indications may arise in the future, both in PD (palliative care, nonmotor symptoms, withdrawal of oral dopaminergic medication), and outside PD, with promising work in neuroprotection or addiction. Springer International Publishing 2018-03-15 2018-06 /pmc/articles/PMC5995787/ /pubmed/29546602 http://dx.doi.org/10.1007/s40268-018-0230-3 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review Article
Auffret, Manon
Drapier, Sophie
Vérin, Marc
The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future
title The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future
title_full The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future
title_fullStr The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future
title_full_unstemmed The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future
title_short The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future
title_sort many faces of apomorphine: lessons from the past and challenges for the future
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995787/
https://www.ncbi.nlm.nih.gov/pubmed/29546602
http://dx.doi.org/10.1007/s40268-018-0230-3
work_keys_str_mv AT auffretmanon themanyfacesofapomorphinelessonsfromthepastandchallengesforthefuture
AT drapiersophie themanyfacesofapomorphinelessonsfromthepastandchallengesforthefuture
AT verinmarc themanyfacesofapomorphinelessonsfromthepastandchallengesforthefuture
AT auffretmanon manyfacesofapomorphinelessonsfromthepastandchallengesforthefuture
AT drapiersophie manyfacesofapomorphinelessonsfromthepastandchallengesforthefuture
AT verinmarc manyfacesofapomorphinelessonsfromthepastandchallengesforthefuture